BioNTech’s (BNTX) “Buy” Rating Reaffirmed at Jefferies Financial Group

Jefferies Financial Group restated their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research note released on Wednesday morning,MarketScreener Latest Ratings reports. The brokerage currently has a $151.00 price objective on the stock.

A number of other analysts have also recently commented on BNTX. JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $121.00 to $120.00 and set a “neutral” rating for the company in a research note on Thursday, October 23rd. HC Wainwright raised their price target on shares of BioNTech from $136.00 to $140.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Wells Fargo & Company set a $150.00 price objective on shares of BioNTech and gave the company an “overweight” rating in a report on Tuesday, August 5th. UBS Group upped their target price on BioNTech from $115.00 to $117.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Finally, Berenberg Bank restated a “buy” rating on shares of BioNTech in a research note on Tuesday, November 25th. Ten investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $136.42.

BioNTech Stock Up 0.6%

BioNTech stock opened at $96.73 on Wednesday. BioNTech has a 1-year low of $81.20 and a 1-year high of $129.27. The business has a fifty day moving average price of $102.93 and a 200-day moving average price of $105.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02. The stock has a market capitalization of $21.78 billion, a price-to-earnings ratio of -36.78 and a beta of 1.30.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The business had revenue of $1.78 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter last year, the business posted $0.81 earnings per share. The company’s quarterly revenue was up 22.0% compared to the same quarter last year. Equities research analysts forecast that BioNTech will post -3.88 EPS for the current fiscal year.

Institutional Investors Weigh In On BioNTech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BNTX. Costello Asset Management INC acquired a new stake in BioNTech in the 1st quarter valued at about $91,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of BioNTech by 30.0% in the first quarter. Charles Schwab Investment Management Inc. now owns 243,468 shares of the company’s stock valued at $22,170,000 after purchasing an additional 56,113 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of BioNTech by 9.1% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,494 shares of the company’s stock valued at $227,000 after purchasing an additional 209 shares in the last quarter. Invesco Ltd. grew its position in shares of BioNTech by 643.7% in the first quarter. Invesco Ltd. now owns 645,142 shares of the company’s stock valued at $58,747,000 after purchasing an additional 558,389 shares during the last quarter. Finally, HighTower Advisors LLC increased its stake in shares of BioNTech by 46.2% during the 1st quarter. HighTower Advisors LLC now owns 16,077 shares of the company’s stock worth $1,464,000 after purchasing an additional 5,079 shares in the last quarter. 15.52% of the stock is owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.